评估羟基脲对儿童镰状细胞贫血的长期获益
该准实验研究纳入2010至2021年2147例HbSS/HbSβ0镰状细胞贫血患儿,采用双重差分和动态事件研究分析羟基脲的长期效应。羟基脲使用与每年急诊就诊次数减少(ATT -0.36次/年,95%CI -0.57至-0.16)和每年住院天数减少(ATT -0.84天/年,95%CI -1.51至-0.17)相关,且效应随时间持续;血红蛋白平均升高(ATT 0.56 g/dL,95%CI 0.39-0.73),但持续升高仅见于实验室指标提示依从性良好的亚组。
要点
- 羟基脲使用与镰状细胞贫血患儿每年急诊就诊次数减少相关(ATT -0.36次/年,95%CI -0.57至-0.16)。
- 羟基脲使用与每年住院天数减少相关(ATT -0.84天/年,95%CI -1.51至-0.17),效应随时间持续。
- 血红蛋白平均升高(ATT 0.56 g/dL,95%CI 0.39-0.73),持续升高仅见于依从性良好亚组。
核心结论
- 羟基脲在镰状细胞贫血患儿中具有持续的临床获益,可减少急诊就诊次数和住院天数。
- 这些发现为临床医生和家庭提供了关于羟基脲长期疗效的视角,并强调持续依从性咨询对优化临床获益的重要性。
- 该研究设计为在真实世界环境中严格且因果地评估其他镰状细胞贫血特异性治疗(如干细胞移植和基因治疗)提供了方法学框架。
研究设计与样本
- 准实验研究,采用当代双重差分和动态事件研究分析。
- 纵向队列纳入2010年至2021年2147例镰状细胞贫血患儿(血红蛋白SS或血红蛋白SSβ0,HbSS/HbSβ0)。
主要发现
- 羟基脲使用与每年急诊就诊次数减少相关(ATT -0.36次/年;95%CI -0.57至-0.16),效应随时间持续。
- 羟基脲使用与每年住院天数减少相关(ATT -0.84天/年;95%CI -1.51至-0.17),效应随时间持续。
- 羟基脲使用时血红蛋白浓度平均升高(ATT 0.56 g/dL;95%CI 0.39-0.73),但持续效应仅在具有良好依从性实验室标志物的亚组中观察到。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hydroxyurea is the primary disease-modifying medication for sickle cell anemia (SCA), but its long-term effects, particularly how these effects change over time, are not well understood. This study aimed to quantify the effects of hydroxyurea on clinical and laboratory outcomes in children with SCA over a prolonged period of use. We conducted a quasi-experimental study using contemporary difference-in-differences and dynamic event study analyses on a longitudinal cohort of 2147 children with SCA (hemoglobin SS or hemoglobin SSβ0, HbSS/HbSβ0) from 2010 to 2021. The primary outcomes included emergency department (ED) visits per year, hospital days per year, and annual average hemoglobin concentration. Hydroxyurea use was associated with fewer ED visits per year (average treatment effect on the treated [ATT], -0.36 visit per year; 95% confidence interval [CI], -0.57 to -0.16) and fewer hospital days per year (ATT, -0.84 d/y; 95% CI, -1.51 to -0.17) with sustained effects over time. On average, the hemoglobin concentration increased with hydroxyurea use (ATT, 0.56 g/dL; 95% CI, 0.39-0.73), but the sustained effect was observed only among the subgroup with laboratory markers of good adherence. This study demonstrates that hydroxyurea has sustained clinical benefits in reducing ED visits and hospital days across years of use in children with SCA. These findings provide perspective for clinicians and families regarding the long-term efficacy of hydroxyurea in pediatric SCA management and underscore the importance of ongoing adherence counseling to optimize clinical benefit. Furthermore, this study design provides a methodological framework for rigorously and causally evaluating other SCA-specific treatments, such as stem cell transplant and gene therapy, in real-world settings.
引用
- George P, Kalmus G, Lane PA, et al. Evaluating the long-term benefits of hydroxyurea in pediatric sickle cell anemia. Blood Adv. 2025. PMID: 40238672. doi:10.1182/bloodadvances.2024015564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。